Catherine M Rogers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Catherine M Rogers has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Anne-Claude Gingras
Lunenfeld-Tanenbaum Research Institute, Sinai Health
1 shared publication - Chris Wells
Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK
1 shared publication - Claire Strain-Damerell
Structural Genomics Consortium, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK
1 shared publication - Clarence Yapp
Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK
1 shared publication - Jean-Philippe Lambert
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, ON M5G 1X5, Canada
1 shared publication - Martin Philpott
Botnar Research Centre, Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, NIH Research Oxford Biomedical Research Unit (BRU), and
1 shared publication
Latest Publications
- Open Access
- 13 July 2014
- Published by Springer Nature in Epigenetics & Chromatin
- Vol. 7 (1) , 14
Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching
Acetylation of lysine residues in histone tails plays an important role in the regulation of gene transcription. Bromdomains are the readers of acetylated histone marks, and, consequently, bromodomain-containing proteins have a variety of chromatin-related functions. Moreover, they are increasingly being recognised as important mediators of a wide range of diseases. The first potent and selective bromodomain inhibitors are beginning to be described, but the diverse or unknown functions of bromodomain-containing proteins present challenges to systematically demonstrating cellular efficacy and selectivity for these inhibitors. Here we assess the viability of fluorescence recovery after photobleaching (FRAP) assays as a target agnostic method for the direct visualisation of an on-target effect of bromodomain inhibitors in living cells.
- 13 July 2014
- Published by Springer Nature in Epigenetics & Chromatin
- Vol. 7 (1) , 14
Open AccessAssessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching
Acetylation of lysine residues in histone tails plays an important role in the regulation of gene transcription. Bromdomains are the readers of acetylated histone marks, and, consequently, bromodomain-containing proteins have a variety of chromatin-related functions. Moreover, they are increasingly being recognised as important mediators of a wide range of diseases. The first potent and selective bromodomain inhibitors are beginning to be described, but the diverse or unknown functions of bromodomain-containing proteins present challenges to systematically demonstrating cellular efficacy and selectivity for these inhibitors. Here we assess the viability of fluorescence recovery after photobleaching (FRAP) assays as a target agnostic method for the direct visualisation of an on-target effect of bromodomain inhibitors in living cells.